#Neuroscience Congress. | Explore Tumblr posts and blogs

atoasttotheendoftheworld · 2 years ago

Text

More specific facts/headcanons about some characters/OCs from "My brother is an only child" ('cause I'm actually writing, miracle!) for testing the waters, sorry

The Neji-Tenten-Lee trio + Kakashi's regency as Kage

after the 4th Great Shinobi War ended, Tenten and Lee insisted that Neji must be given the honor and respect he has always deserved; expressing blatant disapproval and harsh criticism toward the Hyūga Clan

Tenten openly suggested to the whole Shinobi Council to go to hell, as a response to their denial to support and approve new legislation for non-conventional marriage and adoption rights

Lee is one of the most enthusiastic supporters, organizers and frequently leader of protest parades, organized by the newly founded Organization for Equal Civil Rights

one of Konoha's largest public parks is the new Wakamono Kōen, commissioned by the Hogake and inaugurated by him during the first spring after the end of the war, it was named in Maito's honor and features a long promenade route with aerobic exercises functioning as an open-air gym

the Seishun no Hi dōjō has been established by Lee, with the purpose of providing public lessons to all age groups and social classes, both civilian and not; to ensure free lessons for those who cannot afford it, some funding is provided by the Konoha local administration as well as by those who can afford to pay a monthly fee

Tenten recently entered the newly modernized Department of Investigation and Forensic Science, in the ANBU Commando, as a bukijutsu and kenjutsu specialist

Kakashi granted, for whomever applied, official advancement to jōnin to survivors of wartime

also privately financed the recently established Center for Mental Health in Konoha Hospital, promoting and pushing for Congress and Council to acknowledge the need to educate specialists in neuroscience and psychology

through private studies and support from Kakashi and Tsunade, Tenten is now officially recognized as an expert in fūinjutsu

recently Lee and his singular inability to mold and master chakra are subject to medical and scientific research, based on the premise that he is essentially capable of using minimal chakra flow unlike most civilians who cannot at all, yet his chakral flow becomes unsteady and unmanageable, effectively shutting down, whenever he tries to use it for any techniques involving large amounts of it

The Aburame reforms, Shino & Shujin

the orphanage facility, formerly in the ownership of private businessmen, transitioned to public management and specifically to the Fund for Juvenile Psychophysical Healthcare headed and initiated by Aburame Shujin

the Aburame Clan financed the establishment of a facility operated by highly qualified medical staff and teachers both civilian and not, alongside a complex of family houses, for all war orphans and families in socio-economic difficulties

Shino recently pursued specific studies in education and signed up as a teacher for civilians and the Academy; he also theorized about the necessity of changes in the learning approach offered at the Academy

the No-Profit Organization Yellow Ladybug has been founded, by the Aburame Clan, with strong support from Councilor Aburame Shujin, to collect donations and funds to allow the proper maintenance of all facilities offering help for minors and adolescents, in addition to promote initiatives for equal rights and better social inclusion for youngsters with disabilities and/or chronic illnesses

after many years, through Shujin's persistence in the Council of Shinobi, the first Counseling Centers for students who feel in need of any kind of support have arisen in the Konoha Academy and in all civilian public schools

recently Shino is working to ensure that specific courses for teachers, both Academy and civilian, are instituted for the purpose of understanding that not all students experience the same learning patterns and therefore it is imperative to identify the strengths of each individual to advance as a group

in assistance to Shujin and other teachers monitoring Naruto's progress in learning about bureaucracy and administration, Shino proposed to help by implementing his recent theories about individual learning patterns

Shino is currently working both as a teacher in a Civilian Public School and as an assistant teacher at the Academy

The misfits, Ryouga & Yumiko

both slaves of the Yasome Clan, grew up in Ishigakure, fatherless children, they lived purely by the law of survival of the fittest

son of a woman who had to sell herself to provide for their survival, Ryouga underwent genetic experiments in the Yamagumo Clan before he sold himself to the Yasome Clan

a mercenary and killer, he is one of the Clan's most proficient, his status as a slave is marked with the Cursed Seal applied to his pectoral

daughter of a concubine of the previous Yasome Clan Leader, Yumiko bears the Cursed Seal on her back and has been a slave since birth

occasionally used as a mercenary, but mostly exploited as a entertainer for men

Yumiko's childhood memories are mostly confused and vague, the clearest ones are from her thirteenth year; frequently experiences nightmares and suffers from insomnia and night terrors

Ryouga recalls vividly that he was born elsewhere and was raised alongside other orphans, older than him, and he knows all of his mother's sacrifices to raise him well; he considers her an hero and idolizes her

Yumiko's natural beauty and prosperous physique brought her to be overly sexualized by the clansmen and exploited for her appearance as she grew up

Ryouga would probably be the richest man in the Clan if it weren't that all his mercenary gains go solely to the Leader's vaults

of all the forced aberrant deeds, the most unpleasantly memorable was, for Ryouga, a slaughter of innocents in the proximity of Kusagakure

of the few times Yumiko was used as a mercenary, one in particular, in a village on the border of the Land of Fire, stuck with her

both got caught up in the 4th Great Shinobi War, unaligned, purchased by some Land, as many other villages akin to Ishigakure

20 notes · View notes

narcissistpsychopath-abuse · 11 days ago

Text

Sam Vaknin, Member of the Organizing Committee of 3rd World Congress on Advances in Mental Health and Psychiatry, Amsterdam, March 2025

Additional international conferences on mental health, neuroscience, brain studies, psychology, and psychiatry

0 notes

pharmaconferenceandexpo · 12 days ago

Text

Track 22: Neuropharmacology CALL FOR ABSTRACTS:- "Step Into the Limelight – Submit Your Abstract Now! “Don’t Miss the 15th Digital Pharmaceutical Innovations Exhibition & Congress! Join us May 14-16, 2025, in San Francisco or online!" 🔗 Submit your abstract here: Submit Abstract 📅 Submission Deadline: January 31, 2025 #DigitalPharmaceutical #Neuropharmacology #BrainHealth #NeuroScience #DrugDiscovery #PharmaInnovation #NeuroResearch #CNSDisorders #MentalHealthMatters #NeuroDrugs #NeurologyUpdates #Pharmacology

0 notes

resmamucg · 23 days ago

Text

Turn Heads and Build Connections: Why Exhibiting Matters at the 5th World Neuroscience, Neurology, and Brain Disorders Congress | January 14-16, 2026 | Abu Dhabi, UAE The neuroscience and neurology fields are at the forefront of innovation, with groundbreaking research and advancements shaping how we understand and treat brain disorders. The 5th World Neuroscience, Neurology, and Brain Disorders Congress, taking place in Abu Dhabi from January 14-16, 2026, is a premier event where the brightest minds in the field converge to exchange ideas, share breakthroughs, and drive the future of brain health. For businesses and organizations working in neuroscience, neurology, and brain disorder treatment, exhibiting at this esteemed congress is an unparalleled opportunity to showcase your expertise, build connections, and position your brand as a leader in this ever-evolving field. Why Exhibiting at the Neuroscience Congress Matters

Unparalleled Visibility:

Exhibiting at the 5th World Neuroscience Congress places your organization in the spotlight, giving you the chance to showcase your products, services, and research to a highly engaged audience. From groundbreaking technologies to innovative therapies and diagnostic tools, this event offers the perfect platform to highlight your contributions to the field.

Engage with Global Experts:

The congress attracts a diverse audience of neurologists, neuroscientists, researchers, clinicians, and industry leaders from across the globe. Exhibiting provides direct access to these experts, allowing you to engage in meaningful conversations, exchange ideas, and explore potential collaborations.

Showcase Cutting-Edge Innovations:

Whether you’re introducing a revolutionary medical device, presenting the latest in neuroimaging technology, or unveiling new pharmaceutical advancements, the congress provides the ideal venue for live demonstrations and presentations. This hands-on approach helps attendees understand the practical applications of your innovations and their impact on patient outcomes.

Strengthen Your Brand's Credibility:

Being an exhibitor at a prestigious event like the 5th World Neuroscience Congress reinforces your organization’s reputation as a key player in the field. It positions your brand as an innovator committed to advancing neuroscience, neurology, and brain disorder research and treatment.

Build Strategic Partnerships:

The congress isn’t just about showcasing—it’s about connecting. Exhibiting gives you access to like-minded professionals who are open to collaborations, whether it’s joint research, clinical trials, or distribution partnerships. These connections can open doors to new opportunities and help your organization grow.

Gain Market Insights:

As an exhibitor, you’ll have a front-row seat to the latest trends, research findings, and technological advancements in neuroscience and neurology. This invaluable insight can help inform your organization’s strategic direction and ensure you remain ahead of the competition. What You Can Expect as an Exhibitor

Prime Location and Maximum Exposure:

The exhibition area is strategically designed to encourage foot traffic and maximize interaction between attendees and exhibitors. From high-visibility booth locations to opportunities for interactive displays, you’ll have the tools to capture attention and leave a lasting impression.

Networking Opportunities:

The congress features dedicated networking sessions, panel discussions, and workshops that bring together exhibitors and attendees in dynamic and engaging ways. These moments provide the perfect setting to establish relationships that could evolve into long-term collaborations.

Comprehensive Exhibitor Support:

The event organizers provide tailored support to help you make the most of your exhibition experience. From booth setup to marketing assistance, you’ll have access to resources that ensure your presence is impactful and seamless. How to Make the Most of Your Exhibition Experience

Design an Eye-Catching Booth:

Your booth is your first impression—make it count. Focus on creating an engaging and interactive space that draws attendees in and communicates your brand’s story. Use digital displays, hands-on demonstrations, and branded materials to leave a memorable impression

Offer Live Demonstrations:

Attendees are more likely to engage with products they can see in action. Whether it’s a new diagnostic tool, treatment protocol, or research process, offering live demos will capture attention and showcase the real-world value of your offerings.

Leverage Marketing Before and During the Event:

Promote your presence at the congress through your website, email campaigns, and social media. Use event hashtags and share sneak peeks of your exhibit to generate excitement. During the event, encourage attendees to visit your booth by hosting mini-events, giveaways, or exclusive presentations.

Network Actively:

Beyond your booth, take advantage of the congress’s networking events and social gatherings to build connections. Approach conversations with a collaborative mindset, focusing on how your organization can work with others to advance the field.

Follow Up with Leads:

The connections you make during the congress are just the beginning. Ensure you have a system in place to collect contact information and follow up promptly after the event. Personalized communication can help turn leads into lasting partnerships. Why Abu Dhabi? As a global hub for innovation and cultural exchange, Abu Dhabi offers an inspiring setting for this world-class congress. The city’s state-of-the-art facilities and vibrant atmosphere provide the perfect backdrop for meaningful discussions and groundbreaking discoveries in neuroscience and brain health. Conclusion Exhibiting at the 5th World Neuroscience, Neurology, and Brain Disorders Congress is more than a business opportunity—it’s a chance to be part of a movement shaping the future of neuroscience and brain health. By showcasing your innovations, engaging with global experts, and building strategic partnerships, you’ll position your organization at the forefront of this dynamic field. Don’t miss this opportunity to turn heads and build connections that matter. Register as an exhibitor today and take your place among the leaders driving the future of neuroscience, neurology, and brain disorder solutions. See you in Abu Dhabi!

#neuroscience #neurology #neurologist #cognitiveneuroscience

0 notes

pshychiatrysummit · 2 months ago

Text

Addiction Therapy

International Conference on Addiction Therapy: Bridging Science, Recovery, and Holistic Care

The Addiction Therapy Conference, with its theme "Innovative Approaches in Addiction Therapy: Bridging Science, Recovery, and Holistic Care," is set to take place on September 22-23, 2025, in Barcelona, Spain. This groundbreaking event will bring together leading experts, researchers, practitioners, and advocates to explore cutting-edge solutions to address addiction challenges worldwide.

A Global Platform for Innovation and Collaboration

The International Addiction Conference is a premier event that fosters collaboration among addiction specialists and professionals from allied fields. With a focus on innovation and holistic recovery, the conference offers a robust platform to exchange ideas, showcase research, and develop actionable strategies for tackling addiction. The conference features several specialized tracks, such as the Substance Use Conference, the Forensic Psychology Conference, and the Social Media Addiction Conference.

Highlights of the Addiction Therapy Congress

This Addiction Therapy Congress is designed to provide attendees with deep insights into modern therapeutic approaches. Key features include:

Plenary and Keynote Sessions: Led by world-renowned experts, these sessions will address critical topics in addiction therapy, from advancements in neuroscience to innovative holistic care models.

Interactive Workshops: Engage in hands-on experiences that cover practical applications for treating drug addiction and behavioral disorders.

Networking Opportunities: The Addiction Meeting and Recovery Summit offer platforms to connect with peers, share expertise, and build lasting professional relationships.

Key Themes Explored at the Addiction Conference

Innovative Treatment Approaches: A significant focus of the Addiction Symposium is on new therapeutic modalities that bridge science and holistic care, providing effective solutions for long-term recovery.

Behavioral Addictions: The growing prevalence of social media and technology-related addictions will be addressed in the Social Media Addiction Conference, with sessions on assessment and intervention strategies.

Legal and Forensic Implications: The Forensic Psychology Conference will explore the intersection of addiction and the legal system, highlighting pathways to rehabilitation over punishment.

Substance Use and Abuse: The Substance Abuse Conferences will cover critical issues such as the opioid crisis, emerging drug trends, and effective community-based recovery models.

Why Attend the Addiction Therapy Events?

Attending the Addiction Therapy Events provides unparalleled opportunities to:

Stay informed about the latest developments in substance abuse treatment and research.

Engage with experts at the Addiction Symposium to explore cutting-edge therapeutic techniques.

Network with global leaders at the Recovery Summit and Addiction Meeting.

Gain insights from specialized tracks, including the Substance Use Conference and the Drug Addiction Conference.

Related Conferences:

A Unique Opportunity for Holistic Care Integration

The conference aims to redefine addiction therapy by integrating science, recovery, and holistic care. Attendees will gain valuable insights into treatments like mindfulness-based interventions, community therapy models, and family-focused recovery strategies, ensuring a comprehensive approach to healing.

Mark Your Calendar

The Addiction Therapy Conference in Barcelona promises to be a transformative event for anyone involved in addiction care and advocacy. Whether you're a seasoned professional or a newcomer to the field, this event offers valuable resources and connections to enhance your practice.

Join us on September 22-23, 2025, in Barcelona, Spain, to be part of the solution in addressing the global addiction crisis. For more details and to register, visit the official conference website. Don’t miss this chance to be at the forefront of addiction therapy advancements!

For More Details:

www.pshychiatrysummit.com +1 630 768 1199 [email protected] 16192 Coastal Highway Lewes, Delaware, USA 19958

#Addiction conference #Addiction symposium #Drug addiction conference #Addiction therapy congress #Addiction Therapy conference #Addiction Therapy Events #Recovery summit #Substance use conference #International addiction conference #Forensic psychology conference #Social media addiction conference #Substance abuse conferences #Addiction meeting.

0 notes

parkinson-verkeersdeelnemer · 3 months ago

Text

¡Nieuws Parkinson, verkeer en meer!

© Foto AI ¡Nieuws Parkinson, verkeer en meer! TOPIC: > Verenigingsdag en ALV Parkinson Vereniging 16 november 2024 van 11:00 uur tot 16:30 uur < — Parkinson Today (1 november 2024), the 4th Annual Congress of the Dutch Parkinson Scientists . ‘Translational Neuroscience’ was organized in Utrecht bij the team of Jeroen Pasterkamp. It was great to see the highlights of Parkinson(ism) research in…

View On WordPress

0 notes

neurologyworldconference · 3 months ago

Text

4th Edition of Neurology World Conference NWC 2025

Precision global Conferences cordially invite you to our conference Neurology World Conference (NWC 2025) HYBIRD EVENT Date September 5 to 7, 2025, in Boston, Massachusetts, USA.

Conference theme: “The Complex Brain: Innovations in Neurology and Neuroscience.”

4th Edition of Neurology World Conference, September 05 to 07, 2025, in Boston, Massachusetts, USA, focuses on the crucial progression of innovations and breakthroughs through cutting-edge neurology research and practice. We aim to explore the new streamlines in the field and bridge neuronal Shortfalls in the industry. Neurology World Conference focuses on the crucial progression of innovations and breakthroughs through cutting-edge neurology research and practice. We aim to explore the new streamlines in the field and bridge neuronal Shortfalls in the industry.

NWC 2025 agenda mainly focuses on bringing on neurologists, neuro specialists, neuro physicians, academicians, medical professionals, and industry specialists from all the multi-disciplines to join us. We invite you to disseminate the most recent findings among your colleagues. The upgrading technology and fast-paced lifestyles are diluting the mental health of people these days, giving rise to many such neurological diseases. Over the past 25 years, there has been an increase in neurological illnesses that cause illness, death, or long-term disability worldwide. Because of these problems, mortality rates are rising daily among people worldwide.

For more information: https://www.neurologyworldconference.com/

For Abstract Submission: https://www.neurologyworldconference.com/abstract-submission.php

To register: https://www.neurologyworldconference.com/registration.php

Reach out at: [email protected]

Organiser:

Precision Global Conference: https://precisionglobalconferences.com/

Address: 601 King St Ste 200 #853 Alexandria, VA 22314 United States

Email: [email protected]

Phone: +1-571-5561014

0 notes

evoldir · 3 months ago

Text

Fwd: Conference: Lisbon_Portugal.EvolutionaryEthology.Dec5-7

Begin forwarded message: > From: [email protected] > Subject: Conference: Lisbon_Portugal.EvolutionaryEthology.Dec5-7 > Date: 17 October 2024 at 07:34:36 BST > To: [email protected] > > > Dear colleagues and friends, > > It is with great enthusiasm that I invite you to the XXI edition of the > Portuguese Ethological Society (SPE) Congress, which will take place > in Lisbon on December 5th, 6th, and 7th, 2024, at the Luso-American > Foundation (FLAD). This event is organized in partnership with MARE - > Marine and Environmental Sciences Centre and the Faculty of Sciences > of the University of Lisbon. We kindly ask you to share this invitation > widely within your institutions and networks. > > The congress is designed to foster dialogue across multiple disciplines, > with a particular focus on how ethology, behavioural ecology and how > it intersects with evolutionary biology. Topics such as behavioural > ecology, social learning, and cultural evolution are central themes > of the event. These areas are key subfields of evolutionary biology, > which is reflected in the structure of the congress and the selection > of our plenary speakers. > > We are pleased to announce an outstanding panel of speakers, two of whom > will directly address evolutionary concepts: > > - Prof. Kevin Laland (University of St Andrews, Scotland) will discuss > themes from his upcoming book, "Evolution Evolving: The Developmental > Origins of Adaptation and Biodiversity" > > - Dr. Sally Keith (Lancaster University, England) will introduce the > concept of "Macrobehaviour: Behavioural Variation Across Space, Time, > and Taxa", exploring evolutionary implications of large-scale behavioural > patterns. > > The event will also include contributions from Dr. Megan Carey > (Champalimaud Research, Portugal) and Dr. João Saraiva (CCMAR - > University of Algarve, Portugal), bringing valuable insights from > neuroscience and animal welfare, respectively. These talks, combined > with workshops, poster sessions, and oral presentations, aim to enrich > our understanding of animal behaviour. > > A highlight of this edition will be a debate on the impact of April > 25th on science and scientific societies in Portugal, marking the > 50th anniversary of this pivotal moment in the country's history. The > discussion will focus on how this event shaped the evolution of research, > education, and the scientific community. > > We encourage your participation through oral or poster presentations, with > the submission deadline extended to October 18th (NEW DATE). Additionally, > we welcome workshop proposals for activities on December 7th at the Guia > Maritime Laboratory in Cascais. > > For more details about the congress, including submission > guidelines and the full program, please visit our official website > (https://ift.tt/HsDxLR1) and follow us on social media. > > We look forward to your participation in making this congress a success > and advancing discussions on ethology and evolutionary biology. > > Kind regards, > > José Ricardo Paula, PhD > President, Portuguese Ethological Society (SPE) > ISPA - Rua Jardim do Tabaco, 34 1149-041 Lisboa, Portugal > www.etologia.pt > [email protected] > > > > > José Ricardo Paula, PhD > > Presidente > > Sociedade Portuguesa de Etologia > ISPA - Rua Jardim do Tabaco, 34 1149-041 Lisboa, Portugal > www.etologia.pt > [email protected] > > > José Ricardo Paula

#IFTTT #Email

0 notes

reasoningdaily · 4 months ago

Text

Science: Did a top NIH official manipulate Alzheimer's and Parkinson’s studies for decades?

In 2016, when the U.S. Congress unleashed a flood of new funding for Alzheimer’s disease research, the National Institute on Aging (NIA) tapped veteran brain researcher Eliezer Masliah as a key leader for the effort. He took the helm at the agency’s Division of Neuroscience, whose budget—$2.6 billion in the last fiscal year—dwarfs the rest of NIA combined.

As a leading federal ambassador to the research community and a chief adviser to NIA Director Richard Hodes, Masliah would gain tremendous influence over the study and treatment of neurological conditions in the United States and beyond. He saw the appointment as his career capstone. Masliah told the online discussion site Alzforum that “the golden era of Alzheimer’s research” was coming and he was eager to help NIA direct its bounty. “I am fully committed to this effort. It is a historical moment.”

Masliah appeared an ideal selection. The physician and neuropathologist conducted research at the University of California San Diego (UCSD) for decades, and his drive, curiosity, and productivity propelled him into the top ranks of scholars on Alzheimer’s and Parkinson’s disease. His roughly 800 research papers, many on how those conditions damage synapses, the junctions between neurons, have made him one of the most cited scientists in his field. His work on topics including alpha-synuclein—a protein linked to both diseases—continues to influence basic and clinical science.

But over the past 2 years questions have arisen about some of Masliah’s research. A Science investigation has now found that scores of his lab studies at UCSD and NIA are riddled with apparently falsified Western blots—images used to show the presence of proteins—and micrographs of brain tissue. Numerous images seem to have been inappropriately reused within and across papers, sometimes published years apart in different journals, describing divergent experimental conditions.

After Science brought initial concerns about Masliah’s work to their attention, a neuroscientist and forensic analysts specializing in scientific work who had previously worked with Science produced a 300-page dossier revealing a steady stream of suspect images between 1997 and 2023 in 132 of his published research papers. (Science did not pay them for their work.) “In our opinion, this pattern of anomalous data raises a credible concern for research misconduct and calls into question a remarkably large body of scientific work,” they concluded.

Neither Masliah nor the various drug companies, universities, or federal agencies that were provided the dossier have so far rejected or challenged any of its examples of possible misconduct despite being given the material more than 2 weeks ago. And today, the National Institutes of Health (NIH) released a statement saying that following an investigation, it had “made findings of research misconduct” against Masliah for “falsification and/or fabrication involving re-use and relabel of figure panels” in two publications. According to the statement, Masliah no longer serves as NIA’s neuroscience division director, but NIH declined to further clarify his employment status.

Masliah and Hodes, via a spokesperson, declined to reply to detailed questions, provide an interview, or comment on the dossier. NIH Director Monica Bertagnolli also declined to comment. And Masliah did not reply to Science’s requests for raw images and other data related to the examples in suspect papers, or to a new request for comment on the NIH misconduct finding.

The dossier challenges far more studies than the two cited in NIH’s statement, including many that underpin the development and testing of experimental drugs (see sidebar). Masliah’s work, for example, helped win a nod from the U.S. Food and Drug Administration (FDA) for clinical trials of an antibody called prasinezumab for Parkinson’s. Made by Prothena—a company backed by big money—the drug is intended to attack alpha-synuclein, whose build up in the brain has been linked to the condition’s debilitating physical and cognitive symptoms.

But in a trial of 316 Parkinson’s patients, reported in 2022 in The New England Journal of Medicine, prasinezumab showed no benefit compared with a placebo. And volunteers given infusions of the antibody suffered from far more side effects such as nausea and headaches than those in a placebo group who received sham infusions. Prothena is now collaborating in another trial of the drug candidate involving 586 Parkinson’s patients.

The creators of the dossier, who were unaware of NIH’s probe when they spoke with Science, emphasize that they are not themselves accusing Masliah or his colleagues of fraud or misconduct. They note that some of the identified image problems might have been simple errors, and that when images are prepared for publication, some can acquire innocent visual artifacts that resemble improper changes. Distinguishing the two sometimes requires comparison to raw, high-resolution images and other data, which the dossier’s authors did not have. But they say their findings merit formal investigations.

The enormity of apparent problems described in the Masliah dossier stunned 11 neuroscientists who agreed to review it for Science. “Breathtaking,” says neuroscientist Christian Haass of the Ludwig Maximilian University of Munich. “People will, of course, be shocked, as I was. … I was falling from a chair, basically.”

He and the other researchers didn’t personally verify every example of possible misconduct, but they agreed that most of the suspect work cannot reasonably be explained as careless errors or publishing anomalies. “I’m floored,” says Samuel Gandy, a prominent neurologist at the Mount Sinai Alzheimer’s Disease Research Center who was visibly shaken during a video interview. “Hundreds of images. There had to have been ongoing manipulation for years.”

Gandy was disturbed, for example, that Masliah and colleagues seem to have used the same image of a mitochondrion, a cellular energy-producing structure, in two articles on different topics published 2 years apart in different journals. “The bus driver could see that they are identical,” Gandy says.

MASLIAH IS THE SOLE common author on every paper in the dossier, usually taking the first or last position in multiauthor articles. Those positions imply he did the majority of the publication’s work or bears primary responsibility for it, although the others contributed.

Several of the neuroscientists who reviewed the dossier say it seems implausible that Masliah was duped by a colleague. “Given the extended time frame and huge number of differing collaborators and co-authors on these papers, [possible misconduct] by a rogue postdoc or a collaborating scientist doesn’t apply here,” says Tim Greenamyre, director of the University of Pittsburgh Institute for Neurodegenerative Diseases. “I have a hard time believing that he didn’t know, whether he changed the images himself or somebody else did so on his behalf.”

I’m floored ... Hundreds of images. There had to have been ongoing manipulation for years.

Samuel Gandy

Mount Sinai Alzheimer’s Disease Research Center

At a minimum, according to neuroscientists who spoke with Science, the large volume of doubtful images erodes trust in Masliah’s overall body of work. All 11 who reviewed the dossier agree that all his problem papers should be investigated by NIH, scholarly journals, funders, and UCSD. The university declined to comment, and NIH did not say whether it planned or was conducting a broad misconduct investigation into his research. Masliah this week, days after NIH said it concluded its probe, still appeared with Hodes, the NIA director, to give introductory remarks at the start of a national Alzheimer’s summit on the NIH campus.

As a division director, Masliah would hold sway over NIA’s neuroscience funding, according to Alan Leshner, who previously led two other NIH institutes and headed AAAS (publisher of Science) until 2015. In most cases, he says, institutes select grants based on scores awarded by peer-review “study sections.” But institute and division directors can fund preferred projects, such as studies of amyloid, the brain protein linked to Alzheimer’s disease, over better scoring competitors.

“There’s no question that in most cases, a division director … is viewed as someone who has the judgment to set priorities,” Leshner says. They can also alter the direction of a field. If a division director shows interest in a particular aspect of neuro-science related to aging, he adds, “you get [many] proposals in the next round in that area.”

There’s no evidence that Masliah has been a poor steward of NIA’s neuroscience budget or directed it down blind alleys underpinned by suspect data, but NIH’s statement today still leaves many crucial questions unaddressed.

“The volume of papers and resources involved are enormous—as is Dr. Masliah’s leadership and influence on the field, including drug development pipelines,” says Vanderbilt University neuroscientist Matthew Schrag, one of those who helped assemble the dossier. “That makes it a very influential example of possible misconduct.”

MASLIAH, 65, TRAINED in medicine and neuropathology at the National Autonomous University of Mexico (UNAM), earning his medical degree in 1982 and completing a residency in pathology in 1986. He married a U.S. resident who also studied medicine at UNAM. They relocated to San Diego after Masliah’s training.

Soon after, he landed a plum research fellowship in the lab of Robert Terry, a titan in neuropathology and Alzheimer’s research who reportedly received NIH’s first grant for the neurodegenerative condition in the 1960s. “I was incredibly lucky to meet Dr. Bob Terry,” he told a UCSD interviewer in 2016. In a 1990 photo of Terry’s lab staff, a dark-bearded, youthful Masliah stands proudly, arms folded and wearing his trademark large glasses, beside his famous mentor, who died in 2017. Terry and Masliah pioneered the use of an optical imaging method known as confocal microscopy to create high-resolution 3D images of brain cells.

Masliah went on the lead UCSD’s Experimental Neuropathology Laboratory, where he contributed to early work on alpha-synuclein and novel antibody and vaccine approaches to attack Alzheimer’s and Parkinson’s—some of which led to experimental drugs such as prasinezumab that have reached human trials. For Parkinson’s, he also explored antidepressants, and anti-inflammatory drugs or compounds. And for Alzheimer’s, he looked into compounds to decrease the production of amyloid, which builds up in the brain and forms deposits known as plaques outside neurons.

Neurologist Douglas Galasko, who formerly directed the UCSD Alzheimer’s Disease Research Center, where Masliah worked, praises his scholarship and character, calling him “highly collegial and very hardworking.” Galasko co-authored five papers in the dossier, making modest contributions unrelated to apparently doctored images. (He opted not to view the document.)

Galasko says he never heard concerns or doubts about Masliah, whom he describes as “very serious, yet warm and thoughtful, and engaging to have a conversation with.” Those qualities earned him long-term loyalty from investigators working in his lab, Galasko adds. “He’s a very effective spokesperson, organizer, and synthesizer of ideas.” Colleagues at UCSD, he notes, felt enormous pride when Masliah took the helm at NIA’s neuroscience division.

Major impact

Eliezer Masliah’s research on Parkinson’s and Alzheimer’s diseases has enjoyed global influence. His output, as well as the number of citations to his papers, place him among the world’s top 10 scientists in certain subfields (highlighted in red).

“NIA sets the agenda worldwide for age-related diseases,” says Scott Ayton, who directs a neuroscience center at the Florey research institute in Australia, echoing peers in the U.S. and Europe. He was among those who reviewed the dossier and considered the concerns highly credible.

University of Texas at San Antonio neuroscientist George Perry, chief editor of the Journal of Alzheimer’s Disease, describes Masliah’s research as influential and well-regarded, as do other experts in neurodegenerative diseases. In key topics related to Alzheimer’s and Parkinson’s, Masliah frequently ranks in the global top 10 researchers—and often first—by number of papers and citations to them, according to an analysis of data from Dimensions Analytics, a scholarly research data bank from the U.K. company Digital Science (see chart, above). For example, Masliah placed first for papers that use the terms “synuclein” and “synapse.”

His most influential work includes fundamental studies of synaptic damage in mice genetically engineered to mimic various neurodegenerative conditions. “People are very dependent on all of these descriptions,” says Perry, who also reviewed the dossier on Masliah’s research for Science. Many are among the 132 questioned papers, which have racked up more than 18,000 citations, often by leading scholars. “Now I think that work was probably fabricated, in part,” Perry adds, calling the influence of the questioned papers “very problematic.”

BEGINNING IN 2023, forensic image sleuths began to flag a few papers in which Masliah played a central role, posting to PubPeer, an online forum where research publications are discussed and allegations of misconduct often raised. In a few cases, Masliah or a co-author replied or made corrections. Soon after, Science spotted the posts, and because of Masliah’s position and standing decided to take a deeper look.

Schrag, Columbia University neurobiologist Mu Yang, and independent forensic image analyst Kevin Patrick agreed to examine a wider swath of Masliah’s output. (Patrick, a nonscientist who uses the moniker “Cheshire” on social media, had pseudonymously submitted several PubPeer posts on Masliah papers.) In 2023, after a similar request from Science, the same group had assessed work by University of Southern California (USC) Alzheimer’s and stroke expert Berislav Zlokovic. Their dossier of possible misconduct and a subsequent Science report prompted university and NIH investigations, which are apparently ongoing, and led NIH to pause a late-stage clinical trial of a stroke drug based in part on apparently manipulated studies.

For the new dossier, Schrag provided examples, technical context, and expertise on how the findings might affect the promise of prasinezumab and other drugs. Yang took the lead role in identifying and examining questionable images. She used Image- twin, a software program, to assist her own personal scrutiny. (The software, for example, initially spotted the reused mitochondrion image.) Schrag and Yang worked independently of their employers.

Microbiologist and research integrity expert Elisabeth Bik, who also worked on the Zlokovic dossier, contributed other Masliah examples and reviewed and concurred with almost all of the findings. All of the dossier authors worked as volunteers, poring over papers and images in their spare time. The group says it will post many of the examples from the Masliah dossier on PubPeer for others to review; Schrag provided the dossier to NIH, as did Science in the course of producing this story. (NIH’s statement says it had initiated its own investigation much earlier, in May 2023, after receiving allegations from the HHS Office of Research Integrity [ORI].)

In Yang’s analysis of multiple Masliah-authored papers, duplicated sections in some Western blots that had been “seamlessly blended” quickly floated into view, she says. “It tells me someone put a lot of thought and effort into the image … and usually indicates something is very wrong.”

Yang began to see patterns in the apparent image doctoring, which also included images that had been duplicated or seemingly altered by “cloning” portions of them. “I started feeling like a curator or art historian—when you look at a piece of art without the label, you know the artist by the style. Like a painting from Picasso’s blue period,” she adds, “it’s a signature style that I saw in many, many papers—the way they lay out the figures, even the color contrast.”

After finding hundreds of questionable images, the group had more than enough strong signs of misconduct and stopped looking, Yang says. But she suspects similar problems would emerge from a close examination of the hundreds of other Masliah papers.

Making a drug look better?

National Institute on Aging neuroscience chief Eliezer Masliah was senior author of a 2015 study of the Alzheimer’s disease treatment Cerebrolysin in BMC Neuroscience. Brain-tissue images from normal mice and mice engineered to overexpress a mutant form of the tau protein might have been doctored to suggest the drug reduces damage from the tau.

Overlapping copies

In the paper, normal (non-tg) mice show no tau damage. The mutant mice (3RTau) show tau damage unless treated with Cerebrolysin. But a merged image of the younger, normal mouse and the older, treated mutant appear unnaturally similar. Yellow sections are identical.

A series of clones

Dissimilar (red or green) areas within the merged image seem to be caused by efforts to obscure the duplication. Small “cloned” areas within each image are indicated by same-color boxes. The journal’s publisher said it would review the concerns.

YANG AND THE OTHER authors say the ongoing human trials of prasinezumab add to the urgency of their findings. According to Prothena, the drug blocks the spread of toxic alpha-synuclein and might slow the progression of Parkinson’s movement disorders and dementia. Prasinezumab’s documented side effects have not been dangerous. But if it is based on suspect scientific foundations and, as the first clinical results suggest, ineffective, further clinical testing could raise false hopes and divert patients from trials of other experimental drugs.

The concept for prasinezumab emerged from Masliah’s ties to the late Dale Schenk, a UCSD-trained neuroscientist whose research helped pioneer the idea of treating Alzheimer’s and Parkinson’s with vaccines designed to block the buildup of harmful amyloid and synuclein. Masliah, Schenk, and others proposed that immunizing people with benign parts of each protein could spur the immune system to produce antibodies that might block the full, toxic form. Infusing labmade antibodies might have the same effect. Either approach, they hypothesized, could offer a “disease modifying” attack on a condition’s root cause, rather than merely alleviating symptoms.

In a 2016 post on Alzforum, Masliah recalled an early discussion with Schenk on the idea. “Dale and I sat at a coffee shop (his favorite place) next to the Pacific Ocean and drew, on a napkin, the concept of how a potential synuclein vaccine might work,” he said. “People strongly doubted the potential use of a vaccine approach in Alzheimer’s and even more so in Parkinson’s. Dale was one of the few who listened and believed in the idea.”

To pursue that vision Schenk co-founded and served as chief executive of Prothena, spun off in 2012 from the former biopharma company Elan. Masliah worked extensively with Schenk until his death from pancreatic cancer at age 59 in 2016. Four of their joint studies, published between 2005 and 2017, proved foundational for prasinezumab, according to Prothena’s promotional material. Schenk was senior author on two of the papers, Masliah on two. All four used apparently doctored images, according to the dossier, as did other Masliah papers cited in clinical trial reports as important to prasinezumab’s development. Some of the papers suggested Parkinson’s symptoms could be generated in mice engineered to produce alpha-synuclein, and that those symptoms could be reduced by injecting antibodies akin to prasinezumab into the animals.

Greenamyre, a Parkinson’s specialist, says the papers showed an “astonishing level” of apparent image manipulation. But he notes that the image anomalies and the drug’s lack of success so far don’t necessarily mean “that synuclein is a bad target or that targeting it with antibodies is never going to work.” The clinical trial team testing the antibody reported earlier this year in Nature Medicine that a small subgroup of its patients showed hints that prasinezumab slows the worsening of movement symptoms—although the group acknowledged that the finding emerged in a “posthoc analysis,” a secondary review unrelated to the trial’s hypothesis.

Manipulations in key experiment?

Five images in a 2005 paper in Neuron from Masliah and Prothena founder Dale Schenk appear to have been doctored in ways that could influence paper's findings. It is among several papers cited as key to the experimental drug prasinezumab that show apparent falsifications.

Still, “The discovery that key papers supporting this approach contained manipulated figures certainly muddies the waters,” Greenamyre says. He’s now hoping independent studies will determine whether “the rationale for clinical development remains on firm ground—or if it is now a little shaky.”

“We do not interpret these claims as specifically relevant to the current prasinezumab clinical program,” Prothena told Science in a brief statement responding to questions about the image anomalies related to the drug.

Swiss pharma giant Hoffmann-La Roche, which partnered with Prothena to develop prasinezumab in 2013, also supplied a statement in response to Science’s questions, saying it would continue clinical development of the drug. “The evidence supporting targeting alpha-synuclein aggregates as a mechanism of action in [Parkinson’s] is based on a wide range of sources,” it stated. In the interest of scientific integrity, Roche added, “We are working to further understand the details of this matter.”

Roche has agreed to pay Prothena up to $620 million if its drug candidate passes a series of performance goals. So far, Roche has paid $135 million.

Schenk and Masliah shared inventor credit in patents in the U.S. and Europe related to synuclein, amyloids, and related science, and they and their co-inventors assigned the rights to Prothena, UCSD, or both. Numerous other Prothena patents refer to suspect work cited in the dossier. Prothena and NIH did not respond to questions about whether Masliah has received or was promised royalties.

The dossier also questions some of Masliah’s earliest work on alpha-synuclein, raising further doubts about the foundations of Prothena’s drug. A seminal 2000 Masliah article in Science, for example, suggested alpha-synuclein might kill certain brain cells and speed the development of brain deposits called Lewy bodies that are hallmarks of Parkinson’s and are often seen in Alzheimer’s patients. But the paper contains an apparently doctored image and another image the dossier authors deemed questionable.

Other researchers have yet to validate aspects of that study, according to Ayton and neurologist Michael Okun of the University of Florida.

“A single nonreplicable finding is in itself not worrisome,” Okun says. But it raises greater concern in light of “convincing evidence of spliced and cloned images which appeared frequently in the decades following.” He calls it “deeply troubling” that FDA greenlighted human trials of prasinezumab based largely on suspect papers from Masliah’s lab.

People will, of course, be shocked, as I was. ... I was falling from a chair, basically.

Christian Haass

Ludwig Maximilians University Munich

FDA declined to comment on the prasinezumab findings challenged within the dossier. Holden Thorp, editor-in-chief of the Science family of journals, says the journal will “contact the authors [of the 2000 paper] to hear their response to these concerns. If any adjustments are required, we will certainly make them.” (Science’s News department is editorially independent of the journal.)

The new phase 2 trial of prasinezumab is examining whether it might slow the progression of certain movement difficulties caused by Parkinson’s, as the posthoc analysis suggested it might. Roche and Prothena expect to announce preliminary results later this year. The companies would likely decide in 2025 or 2026 on whether to move on to phase 3 trials—larger efficacy experiments needed for possible FDA approval.

The findings in the dossier cast a shadow on the other drug development efforts that rely on Masiah’s challenged work. And they raise questions about the roles and responsibilities of the many prominent scientists as well as more junior researchers who collaborated on some of his suspect experiments.

UCSD neuroscientist Edward Rockenstein, who worked under Masliah for years, co-authored 91 papers that contain questioned images, including 11 as first author. He died in 2022 at age 57. And neuroscientist Robert Rissman worked on 16 of the papers highlighted in the dossier, seven as senior author. He managed biomarkers and brain tissue samples for UCSD’s Alzheimer’s Disease Research Center prior to moving recently to USC, where he occupies a similar role and manages programs that try to move basic research into treatments for patients. Rissman did not reply to requests for comment. USC says it will conduct a confidential review of Rissman’s involvement with Masliah’s work.

Haass questions whether Masliah’s closest collaborators could have remained unaware of the steady stream of apparent image manipulation, even if they were not personally culpable. “I mean, come on,” he says. “They must know.”

Other neuroscientists who spoke to Science urged caution in placing blame. “We should be careful … not to rush to judgment on the generation of researchers who may have been innocent members of this laboratory over the span of 20-plus years,” Okun says. “It is entirely possible that many were unaware of improprieties.”

In its statement today, NIH provided few details about the agency’s own investigation into Masliah’s work, including whether it had examined more than two of his publications. The agency says it has notified ORI of its findings and that the NIA deputy director, Amy Kelley, is also now acting head of the neuroscience division.

Given the NIH misconduct determination and the questions raised by the dossier about more than 100 other papers, many scientists—and perhaps congressional appropriators and the public—might question NIH’s vetting process for key roles and how Masliah retained stewardship of NIA’s billions of neuroscience dollars for so long. “For so important a job, you want somebody who is beyond reproach. You want somebody to be an exemplar of what you aspire to be,” Greenamyre says.

By the time NIA hired Masliah in 2016, image manipulation in scientific papers had already become a general concern. Prominent researchers increasingly faced accusations of image manipulation, plagiarism, or other misconduct—which often proved credible. But a former NIA official who would only speak if granted anonymity says he assumes the agency did not assess Masliah’s work for possible misconduct or data doctoring before he was hired.

Indeed, NIH told Science it does not routinely conduct such reviews, because of the difficulty of the process. “There is no evidence that such proactive screening would improve, or is necessary to improve, the research integrity environment at NIH,” the agency added.

Gandy disagrees. “It has to be part of the process now,” he says.

Greenamyre notes a concern about the episode also voiced by Haass and others who viewed the dossier: “I worry about it giving science a further black eye, just as the public’s confidence in science and scientists is sinking to new depths.” But, Greenamyre says, “In the interest of transparency and scientific integrity, this sad story has to come out.”

Questionable papers underpin other drugs

By Charles Piller

The possibility that neuroscientist Eliezer Masliah doctored images in scientific writings for decades is likely to provoke anxiety among multiple drug companies. The concerns documented by whistleblowers most directly challenge an experimental Parkinson’s therapy developed by Prothena (see main story). But 238 active patents concerning neurological conditions also cite suspect work noted in the dossier, according to data from Dimensions Analytics. And the corporate holders of those patents include dozens of firms at work on treatments.

The Austria-based biopharma company Ever Pharma relied heavily on Masliah’s questioned work in developing Cerebrolysin, a mixture of peptides—short chains of amino acids—derived from pig brains. Eight studies conducted at Masliah’s former lab at the University of California San Diego, funded in part by Ever Pharma, indicated the mixture suppresses brain inflammation, promotes growth of new brain cells, and has other benefits that could help dementia patients.

Small clinical trials of Cerebrolysin have suggested modest cognitive benefits in Alzheimer’s disease and vascular dementia, and Ever Pharma now distributes the drug in dozens of nations to treat dementia and stroke. But no large trials have demonstrated it helps dementia patients, and the Food and Drug Administration has not approved Cerebrolysin for use in the United States. And the eight lab studies used suspect images, according to the dossier.

For example, an article by Masliah and colleagues, in BMC Neuroscience in 2014, described the purported benefits of Cerebrolysin for symptoms of neurodegeneration in mice, including reducing mitochondrial damage. Another, published in Neurotoxicity Research in 2016, concerned mice infected with HIV. It republished what appears to be the same image of a mitochondrion.

A spokesperson for Springer Nature, publisher of Neurotoxicity Research, says the concerns will be examined, and responded to if warranted. Stefan Winter, who heads R&D for Ever Pharma’s neurological division, said in a written statement to Science that none of the challenged work in the dossier “played a crucial role in the clinical development of Cerebrolysin.” But, he added, “We take [the allegations] seriously. We will therefore review Prof. Masliah’s work based on the information you provided and refrain from using data from the mentioned publications until this matter is clarified.”

Another company, Neuropore Therapies, cites seven other papers in the Masliah dossier—all with apparently doctored images—as important to the company’s potential drugs for Parkinson’s. Masliah co-founded Neuropore in 2008 but no longer has any apparent affiliation. The most prominent drug candidate his work helped develop, minzasolmin, is in early clinical trials and targets the protein alpha-synuclein for Parkinson’s.

Masliah also provided imaging services for a 2023 paper in NPJ Parkinson’s Disease. The images, which purportedly show enhanced benefits in mice from minzasolmin, appear to be altered, according to the dossier. The concerns will be examined and responded to if warranted, says the journal’s publisher, Springer Nature. “We stand by our data related to clinical development programs,” said Mark Yung, executive chairman of Neuropore, in a brief written reply to detailed questions.

Minzasolmin has Big Pharma backing. In 2015, Neuropore licensed rights to develop and commercialize it and other molecules to the Brussels-based pharma company UCB for $63 million, plus possible future payments. In turn, the Swiss pharma titan Novartis paid UCB $150 million of a possible $1.5 billion for codevelopment rights for minzasolmin and another experimental drug.

“UCB will investigate the preclinical publication on minzasolmin” described in the Masliah dossier and will respond should “evidence of impropriety emerge,” said company spokesperson Laurent Schots in a written statement. But UCB knows of no “facts or circumstances that raise concerns on the quality, validity, and safety of the ongoing clinical development program for minzasolmin,” which is supported by evidence beyond the suspect Masliah work, Schots added.

Preliminary results for the drug’s efficacy from a clinical trial of 496 people in the U.S., Canada, and Europe could be announced later this year.

#Did a top NIH official manipulate Alzheimer's and Parkinson’s studies for decades?#Questionable papers underpin other drugs #white liars #Parkinson’s and Alzheimer’s diseases #research lies #drug companies lies #tainted research #experiments and lies #NIH #Cerebrolysin #neurotoxicity

0 notes

chonacas · 6 months ago

Text

NuCalm 34 Years Backed Neuroscience with the CEO Jim Poole

Jim Poole says “The human race appears to be in a race to erase the human race.” And at a time when “many people seem to have lost control of their lives,” NuCalm is the perfect remedy, argues Poole, the visionary CEO behind the stress management technology.

“We have a tireless passion for helping people reclaim control of their lives,’ says Poole. “And we can do it with the world’s most powerful neuroscience. We have a culture of service. We don't serve for reciprocity or credit, we serve because we want to, we can, and we love to. It’s our mission and it’s our purpose and we will leave an indelible legacy on the human condition.”

NuCalm is a unique, patented technology that’s clinically proven to lower stress and improve sleep quality. It guides brain wave function reliably, safely, and effectively, with no drugs or side effects, using physics, mathematics, and algorithms in neuroacoustic software underneath music.

Poole, 55, is an accomplished business executive with extensive experience in the healthcare,

biotechnology, medical, financial services, market research, and IT industries. Since 2009 he has managed the strategic direction and ongoing operations of NuCalm, a neuroscience company with an expertise in evidence-based personalized wellness and performance.

NuCalm stands alone as a pioneer in neuroscience that provides humans with the power to change their mental state on demand, without drugs or side effects.

In July 2015, the U.S. Patent Office granted NuCalm the first and only patent for “Systems and Methods for Balancing and Maintaining the Health of the Human Autonomic Nervous System.”

In August 2021, the U.S. Patent Office granted NuCalm the first and only patent for “Methods and devices for applying dynamic, non-linear oscillations and vibrations to elicit a physiological state change in humans.”

Poole has successfully launched global products, managed growth strategies, and optimized business operations for both large and small organizations. Prior to joining NuCalm, he founded Focused Evolution, a global management strategy consulting firm. As Managing Partner, Poole oversaw mergers and acquisitions, due diligence, and growth strategies for venture capital and private equity firms. Focused Evolution managed the largest private equity acquisition in the history of the dental industry for Credit Suisse DLJ Merchant Banking Partners in 2007 and 2008.

Poole has lectured on applied neuropsychobiology, the human stress response, sleep and recovery, brain wave management, and business strategies across the globe, from the Royal College of Physicians in London to the 20th Annual Congress for Brain Mapping and Therapeutics in Los Angeles, from Beijing to St. Petersburg to Parliament to the Pentagon and Quantico to the Toronto Film Festival and the Consumer Electronics Show, the NFL Combine and the Super Bowl, across Europe, the United States, Canada, and India. NuCalm has been featured in The Wall Street Journal, New York Times, FORBES, Access Hollywood, NASDAQ, MSNBC, CBS, the TODAY Show, and more.

Watch and learn more here!

Want 15% off for LIFE on NuCalm - use the code KATIE at checkout.

https://nucalm.com/

Stay connected: https://www.chonacas.com/links/

Business: https://www.linkedin.com/in/katiechonacas/

Check out this episode streaming now in over 100 countries

#arts podcast #entertainment podcast #web3 podcast #nft podcast

0 notes

neurologyevents · 27 days ago

Text

Exploring Psychology and Mental Health: Key Conferences and Events in 2025

Psychology plays a vital role in understanding human behavior, mental health, and cognitive processes. With increasing awareness and research in the field of psychology, attending specialized conferences and events is essential for professionals, researchers, and clinicians. In this blog, we’ll explore major events such as the Psychology Conference and highlight prominent gatherings like the International Psychology Conference 2025 and Psychiatry Conferences.

Psychology Conference 2025

The Psychology Conference 2025 is a premier event that brings together psychologists, researchers, and clinicians from around the globe to discuss the latest developments in psychological research, practice, and mental health care. This conference focuses on exploring new research, evidence-based practices, and innovative approaches to mental health and behavioral sciences.

International Psychology Conference

The International Psychology Conference is a global gathering of professionals dedicated to advancing the field of psychology. It offers a platform for experts to present their research, share knowledge, and discuss strategies for improving mental health outcomes.

Psychology Meetings and Psychiatry Conferences

The Psychology Meetings and Psychiatry Conferences provide valuable opportunities for professionals to exchange insights, collaborate on research, and stay updated on the latest trends and developments in mental health care, treatment strategies, and psychological therapies.

Mental Health Conferences and Psychology Events

The Mental Health Conferences and Psychology Events explore key topics such as depression, anxiety, stress management, and other mental health issues. These conferences aim to foster discussions on prevention strategies, clinical practices, and innovative treatment approaches.

Behavioral Science Congress and Behavioral Science Conference

The Behavioral Science Congress and Behavioral Science Conference emphasize the intersection of psychology, neuroscience, and behavioral research. These events provide insights into human behavior, mental health, and cognitive processes.

Neuroscience Symposium and Depression Meetings

The Neuroscience Symposium highlights the connection between neuroscience and psychology, exploring how brain function impacts mental health. The Depression Meetings focus on the latest research, treatment options, and interventions for managing depression.

Psychology Forum and Psychology Conferences

The Psychology Forum is an interactive platform for professionals to engage in discussions, workshops, and networking opportunities. The Psychology Conference provides a comprehensive look at current research, practices, and challenges in the field of psychology.

Upcoming Conferences:

Conf 7

Attending psychology-related conferences and events is crucial for professionals looking to stay updated on the latest trends, research, and advancements in mental health care. To explore more about upcoming Psychology Conferences in 2025, visit Neurology Events.

#Psychology Conference #Psychology Conference 2025 #International Psychology Conference #Psychology Meetings #Psychiatry Conferences #Mental Health Conferences #Behavioral Science Congress #Psychology Forum #Neuroscience Symposium #Psychology Events #Depression Meetings #Behavioral Science Conference.

0 notes

systemtek · 9 months ago

Text

Intel Builds World’s Largest Neuromorphic System to Enable More Sustainable AI

Intel announced that it has built the world's largest neuromorphic system. Code-named Hala Point, this large-scale neuromorphic system, initially deployed at Sandia National Laboratories, utilizes Intel’s Loihi 2 processor, aims at supporting research for future brain-inspired artificial intelligence (AI), and tackles challenges related to the efficiency and sustainability of today’s AI. Hala Point advances Intel’s first-generation large-scale research system, Pohoiki Springs, with architectural improvements to achieve over 10 times more neuron capacity and up to 12 times higher performance. Hala Point is the first large-scale neuromorphic system to demonstrate state-of-the-art computational efficiencies on mainstream AI workloads. Characterization shows it can support up to 20 quadrillion operations per second, or 20 petaops, with an efficiency exceeding 15 trillion 8-bit operations per second per watt (TOPS/W) when executing conventional deep neural networks. This rivals and exceeds levels achieved by architectures built on graphics processing units (GPU) and central processing units (CPU). Hala Point’s unique capabilities could enable future real-time continuous learning for AI applications such as scientific and engineering problem-solving, logistics, smart city infrastructure management, large language models (LLMs) and AI agents. How It will be Used: Researchers at Sandia National Laboratories plan to use Hala Point for advanced brain-scale computing research. The organization will focus on solving scientific computing problems in device physics, computer architecture, computer science and informatics. “Working with Hala Point improves our Sandia team’s capability to solve computational and scientific modeling problems. Conducting research with a system of this size will allow us to keep pace with AI’s evolution in fields ranging from commercial to defense to basic science,” said Craig Vineyard, Hala Point team lead at Sandia National Laboratories. Currently, Hala Point is a research prototype that will advance the capabilities of future commercial systems. Intel anticipates that such lessons will lead to practical advancements, such as the ability for LLMs to learn continuously from new data. Such advancements promise to significantly reduce the unsustainable training burden of widespread AI deployments. Why It Matters: Recent trendsin scaling up deep learning models to trillions of parameters have exposed daunting sustainability challenges in AI and have highlighted the need for innovation at the lowest levels of hardware architecture. Neuromorphic computing is a fundamentally new approach that draws on neuroscience insights that integrate memory and computing with highly granular parallelism to minimize data movement. In published results from this month’s International Conference on Acoustics, Speech, and Signal Processing (ICASSP), Loihi 2 demonstrated orders of magnitude gains in the efficiency, speed and adaptability of emerging small-scale edge workloads1. Advancing on its predecessor, Pohoiki Springs, with numerous improvements, Hala Point now brings neuromorphic performance and efficiency gains to mainstream conventional deep learning models, notably those processing real-time workloads such as video, speech and wireless communications. For example, Ericsson Research is applying Loihi 2 to optimize telecom infrastructure efficiency, as highlighted at this year’s Mobile World Congress. Hala Point, the world’s largest and Intel’s most advanced neuromorphic system to date, contains 1.15 billion neurons and packages 1,152 Loihi 2 processors produced on Intel 4 process node in a six-rack-unit data center chassis the size of a microwave oven. The system supports up to 1.15 billion neurons and 128 billion synapses distributed over 140,544 neuromorphic processing cores, consuming a maximum of 2,600 watts of power. It also includes over 2,300 embedded x86 processors for ancillary computations. (Credit: Intel Corporation) About Hala Point: Loihi 2 neuromorphic processors, which form the basis for Hala Point, apply brain-inspired computing principles, such as asynchronous, event-based spiking neural networks (SNNs), integrated memory and computing, and sparse and continuously changing connections to achieve orders-of-magnitude gains in energy consumption and performance. Neurons communicate directly with one another rather than communicating through memory, reducing overall power consumption. Hala Point packages 1,152 Loihi 2 processors produced on Intel 4 process node in a six-rack-unit data center chassis the size of a microwave oven. The system supports up to 1.15 billion neurons and 128 billion synapses distributed over 140,544 neuromorphic processing cores, consuming a maximum of 2,600 watts of power. It also includes over 2,300 embedded x86 processors for ancillary computations. Hala Point integrates processing, memory, and communication channels in a massively parallelized fabric, providing a total of 16 petabytes per second (PB/s) of memory bandwidth, 3.5 PB/s of inter-core communication bandwidth, and 5 terabytes per second (TB/s) of inter-chip communication bandwidth. The system can process over 380 trillion 8-bit synapses and over 240 trillion neuron operations per second. Applied to bio-inspired spiking neural network models, the system can execute its full capacity of 1.15 billion neurons 20 times faster than a human brain and up to 200 times faster rates at lower capacity. While Hala Point is not intended for neuroscience modeling, its neuron capacity is roughly equivalent to that of an owl brain or the cortex of a capuchin monkey. Loihi-based systems can perform AI inference and solve optimization problems using 100 times less energy at speeds as much as 50 times faster than conventional CPU and GPU architectures1. By exploiting up to 10:1 sparse connectivity and event-driven activity, early results on Hala Point show the system can achieve deep neural network efficiencies as high as 15 TOPS/W2 without requiring input data to be collected into batches, a common optimization for GPUs that significantly delays the processing of data arriving in real-time, such as video from cameras. While still in research, future neuromorphic LLMs capable of continuous learning could result in gigawatt-hours of energy savings by eliminating the need for periodic re-training with ever-growing datasets. What’s Next: The delivery of Hala Point to Sandia National Labs marks the first deployment of a new family of large-scale neuromorphic research systems that Intel plans to share with its research collaborators. Further development will enable neuromorphic computing applications to overcome power and latency constraints that limit AI capabilities' real-world, real-time deployment. Together with an ecosystem of more than 200 Intel Neuromorphic Research Community (INRC) members, including leading academic groups, government labs, research institutions and companies worldwide, Intel is working to push the boundaries of brain-inspired AI and progressing this technology from research prototypes to industry-leading commercial products over the coming years. Read the full article

0 notes